BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• BioMidwest

  Abbott Introduces Next Generation of Most Widely Used Heart Stent for People With Coronary Artery Disease in Europe

  Abbott today announced it received CE Mark for XIENCE Sierra, the newest generation of the company’s gold-standard XIENCE everolimus-eluting coronary stent system.

  October 30, 2017

   · 

  4 min read
• Biotech Bay

  UCLA Team Reports Positive Topline Results from Double-Blind Trial of NeuroSigma’s Non-Invasive eTNS System for Treatment of Pediatric ADHD

  The trial investigated the effects of eTNS on ADHD as the sole treatment, or “monotherapy.”

  October 30, 2017

   · 

  6 min read
• Drug Development

  Realm Therapeutics Presents Data Highlighting PR013’s Efficacy Reducing Hyperemia and Pruritus Associated with Allergic Conjunctivitis at The ACAAI Scientific Meeting

  Realm Therapeutics today announced the Company presented data for PR013 at the ACAAI Scientific Meeting being held in Boston, MA.

  October 30, 2017

   · 

  4 min read
• Drug Development

  Sierra Oncology Reports Preclinical Data for its Chk1 Inhibitor SRA737 Supporting its Ongoing Clinical Development Strategy

  Sierra Oncology reported preclinical data supporting the ongoing clinical development strategy for its Chk1 inhibitor, SRA737.

  October 30, 2017

   · 

  7 min read
• Bio NC

  vTv Therapeutics to Present on Azeliragon at the 10th Clinical Trials on Alzheimer’s Disease (CTAD)

  vTv is currently studying azeliragon in two identical, randomized, double-blind, placebo-controlled Phase 3 trials investigating its efficacy as a potential treatment of mild Alzheimer’s disease.

  October 30, 2017

   · 

  5 min read
• Drug Development

  Spectrum Pharmaceuticals Announces Initiation of a Multicenter Phase II Trial of Poziotinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Exon 20 Insertion Mutation in EGFR or HER2

  The goal of this Phase 2 trial is to evaluate both the efficacy and safety of poziotinib in patients with non-small cell lung cancer (NSCLC) that is locally advanced or metastatic and have an exon 20 insertion mutation in either EGFR or HER2.

  October 30, 2017

   · 

  5 min read
• Pharm Country

  Ophthotech Corporation to Report Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017

  Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company’s financial results and provide a business update.

  October 30, 2017

   · 

  1 min read
• Genetown

  Centrexion Therapeutics Announces Multiple Data Presentations on CNTX-4975 at the American College of Rheumatology Annual Meeting 2017

  The presentations include 6-month data from the Phase 2b TRIUMPH study assessing the efficacy and safety of CNTX-4975.

  October 30, 2017

   · 

  3 min read
• Business

  AMRI Appoints Paul Feuerman as Senior VP, General Counsel and Head of Business Development

  AMRI today announced that Paul Feuerman has joined the company as senior VP, general counsel and head of business development and will be responsible for leading all AMRI’s legal, M&A, and corporate affairs activities for the company’s locations worldwide.

  October 30, 2017

   · 

  2 min read
• 

  FDA

  FDA Approves Janssen’s New 10 Mg Dosing for XARELTO (Rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism

  The study shows XARELTO 10 mg reduced the risk of recurrent VTE by 74 percent.

  October 30, 2017

   · 

  16 min read